Iovance Biotherapeutics (NASDAQ: IOVA) shares plunged 29.92% in after-hours trading on August 7, 2025, dropping to $1.85 after closing the regular session at $2.64.
The sharp decline followed the company’s Q2 2025 earnings report, which revealed revenue of $59.95 million—missing estimates by nearly 8%—and a larger-than-expected loss of $0.33 per share.
Despite nearly doubling revenue year-over-year, both revenue and earnings fell short of analyst forecasts, triggering a strong negative market reaction.